BRCA1 and carcinoma: Although the presence of pathogenic variants in BRCA1 or BRCA2 is the best genetic predictor for a good clinical response to PARPi therapy, multiple studies have shown that PARPi efficacy is also observed in patients with non-BRCA1/2-deficient carcinomas [4,5,9,12].